AI Insight
This randomized, double-blind trial compared cangrelor (an intravenous P2Y12 inhibitor) versus crushed ticagrelor (an oral P2Y12 inhibitor) in patients with acute myocardial infarction complicated by cardiogenic shock. Cangrelor achieved more effective platelet inhibition than crushed ticagrelor by the end of primary percutaneous coronary intervention. However, cangrelor did not demonstrate non-inferiority to crushed ticagrelor for the primary 30-day clinical endpoint.
Why it matters
This is the first randomized trial specifically examining P2Y12 inhibitor strategies in this high-risk patient population, where optimal antiplatelet therapy remains uncertain. The findings suggest that while cangrelor provides superior platelet inhibition, this pharmacodynamic advantage did not translate into improved clinical outcomes, informing treatment decisions and guiding future research in acute myocardial infarction with cardiogenic shock.
Understand the Science
To our knowledge, this is the first randomised trial to compare P2Y12 inhibitor strategies specifically in patients with AMI-CS. Cangrelor achieved effective platelet inhibition more frequently than crushed ticagrelor at the end of primary percutaneous coronary intervention. Non-inferiority of cangrelor versus crushed ticagrelor was not demonstrated for the primary 30-day clinical endpoint. These trial findings can inform future trials of P2Y12 inhibition strategies in patients with AMI-CS.